R. Oellinger

KRas, in addition to Tp53 is a driver for early carcinogenesis and a molecular target in a mouse model of invasive gastro-esophageal adenocarcinoma

This study identifies KRAS mutation as a driver of invasive gastro-esophageal adenocarcinoma in a mouse model, showing its synergistic role with Tp53 or Rb1 loss and potential as a therapeutic target.

RNF43 is a gatekeeper for colitis-associated cancer

This study identifies RNF43 mutations as a driver of colitis-associated cancer by showing their role in promoting inflammation and dysbiosis in mouse models and human patients.

Genomic and phenotypic stability of fusion-driven pediatric Ewing sarcoma cell lines

This study compares genomic and phenotypic stability of pediatric Ewing sarcoma cell lines to adult carcinoma cell lines over 12 months of culture.

eIF3 mRNA selectivity profiling reveals eIF3k as a cancer-relevant regulator of ribosome content

The paper identifies eIF3k as a regulator of ribosome content in cancer by showing its depletion increases global translation and stress resistance through repression of RPS15A synthesis.

B/T cell crosstalk and aberrant inflammatory IgG exacerbate autoimmune intestinal inflammation

This study identifies B cell-driven inflammatory mechanisms, including aberrant IgG production and CD86-mediated T cell activation, as contributors to exacerbated intestinal inflammation in IBD.

Acinar-to-ductal metaplasia in the pancreas requires a glycolytic switch and functional mitochondria

This study identifies a glycolytic switch and functional mitochondria as essential for acinar-to-ductal metaplasia, a key step in pancreatic carcinogenesis.

A GATA6-centered gene regulatory network involving HNFs and ΔNp63 controls plasticity and immune escape in pancreatic cancer

This paper identifies a GATA6-centered gene regulatory network involving HNFs and ΔNp63 that controls plasticity and immune escape in pancreatic cancer, showing GATA6 loss is necessary but not sufficient for the basal phenotype.

Targeting the ubiquitin-proteasome system in a pancreatic cancer subtype with hyperactive MYC

The paper identifies bortezomib as a potential therapy for MYC hyperactive pancreatic cancer by showing its sensitivity to proteasome inhibition.